SHARE NOW
Global CDMO, Biovian, remains committed to meeting the growing demand for innovative biologics and gene therapies by investing over $55 million to expand its manufacturing facility in Turku, Finland.
Leading CDMO Biovian, provides premium services to biotech companies, specializing in the production of biologics, gene therapies, vaccines, and viral vectors such as adenoviral and AAV therapies. The new 6,400sq ft facility will have house cutting-edge equipment and advanced technologies to support the development of product manufacturing as well as featuring dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture.
Being at the forefront of biopharmaceutical development and manufacturing for two decades, the new investment will enable Biovian to offer end-to-end services, from early-stage development to commercial-scale manufacturing. Biovian has an established reputation for delivering high-quality work, on time, within budget, to a global client base.
Antii Nieminen, CEO of Biovian commented:
“The new manufacturing facility will not only strengthen Biovian’s position as a key player in the CDMO sector but also contribute to the growth of the biopharmaceutical industry in Finland and most of all provide vital therapies to patients suffering from today’s untreatable diseases.”
The expansion is set to be completed in December 2024 and the new facility fully operational by 2025, estimated to create approximately 100 job opportunities in the region which will extend to its existing team of 200.
Pierre Remy, Chairman of the Board, said:
“We are very excited for the opportunities this new world-class facility will bring to Biovian. This significant milestone is built on years of viral vector expertise and demonstrates the commitment of Biovian to support its clients, at the highest possible standard, from early phase to commercial manufacturing.”
As a global CDMO, Biovian supports its customers through all stages up until commercial validation batches, including research, master cell banking, plasmids, proteins, process & analytical development, manufacture, fill/finish and final release for clinical trials.
“Biovian aims to facilitate swift drug development and delivery, reducing time-to-market for its customers, all while creating an enjoyable experience. The new manufacturing facility will increase viral vector capacity, but it will also increase our capacity and flexibility in microbial protein. When the new site is up and running, our existing capacity will be transformed to new microbial protein suites. Thus, both microbial and viral vector customers will benefit from this expansion,” Nieminen added.
Biovian is especially focusing on viral vector production, microbial production of recombinant proteins and GMP plasmid DNA.
Source: Biovian Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
